{"id":"01a1e757-bfad-7599-b2bf-a09e56d0db10","name":"Tigermed take-private of Frontage Holdings and carve-out of target business to Charles River","situation_type":"other","status":"active","start_date":null,"end_date":null,"confidence":0.85,"member_count":3,"summary":"Tigermed, through its wholly owned Hong Kong subsidiary, participates in the privatization of Frontage Holdings and a business split. Tigermed plans to acquire Frontage's non-target mainland China business, while the target business is to be sold to Charles River Laboratories.","place":null,"places":[],"intensity":null,"unknowns":[],"known_at":"2026-11-17T02:30:50.011970Z","actors":[{"id":"01a1e74c-c1d4-74f0-a4bb-31f76c0ac7aa","name":"泰格醫藥","role":"participant"}],"members":[{"kind":"decision","id":"01a1e74c-c233-798b-a1c4-7d2ad9428f54","title":"方達控股目標業務出售予Charles River Laboratories","type_code":"conclude_agreement","status":"proposed","date":null,"role":"part_of"},{"kind":"decision","id":"01a1e74c-c226-7c2b-849d-b5196d42c61e","title":"泰格醫藥擬收購方達控股中國內地非目標業務","type_code":"conclude_agreement","status":"proposed","date":null,"role":"part_of"},{"kind":"decision","id":"01a1e74c-c20a-7bb8-a80c-a4457beaec48","title":"泰格醫藥通過全資附屬香港泰格參與方達控股私有化及業務分拆","type_code":"conclude_agreement","status":"proposed","date":null,"role":"part_of"}],"evidence":null}